NOVEL STRAIN HAVING PROPHYLACTIC OR THERAPEUTIC EFFECT ON CANCER

• Main Authors: Chung, Joo-Yeon, Sohn, Jinyoung, Park, Hansoo, Park, Shinyoung, Lee, Suro, Kim, Wonduck, Yeon, Jae-Sung, Jeong, Areum, Kim, Yun Yeon, Jeon, Hye-Hee, Houh, Youn Kyung, Kim, Sang Gyun, Lee, Eun Ju
• Format: Patent
• Language: English
• Published: 03.11.2022
• Subjects: BEER; BIOCHEMISTRY; CHEMISTRY; COMPOSITIONS THEREOF; CULTURE MEDIA; ENZYMOLOGY; FODDER; FOODS OR FOODSTUFFS; FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BYSUBCLASSES A23B - A23J; HUMAN NECESSITIES; HYGIENE; MEDICAL OR VETERINARY SCIENCE; METALLURGY; MICROBIOLOGY; MICROORGANISMS OR ENZYMES; MUTATION OR GENETIC ENGINEERING; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL; PROCESSES USING MICROORGANISMS; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS; SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS; SPIRITS; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OFNUTRITIVE QUALITIES, PHYSICAL TREATMENT; THEIR TREATMENT, NOT COVERED BY OTHER CLASSES; VINEGAR; WINE

The present invention relates to a novel Bifidobacterium bifidum MG731 strain and a composition for preventing or treating cancers, comprising the same. Specifically, the Bifidobacterium bifidum MG731 strain of the present invention has effects of inhibiting the proliferation of cancer cells, decreasing the mobility of cancer cells, inhibiting the neoangiogenesis, and increasing the anticancer immune response as well as reducing the expression of inflammatory factors, thereby having effects of preventing or treating cancers or inflammatory diseases. In addition, when used in combination with an anticancer chemotherapeutic agent or an anticancer immunotherapeutic agent, the Bifidobacterium bifidum MG731 strain of the present invention exhibits a better anticancer effect. In addition, the present invention relates to a novel Lactococcus lactis GEN3033 strain and a composition for preventing or treating cancers, comprising the same. Specifically, the Lactococcus lactis GEN3033 strain of the present invention exhibits effects of directly inhibiting the proliferation of cancer cells and enhancing immunity, thereby having effects of preventing or treating cancers. In particular, the strain has an excellent anticancer effect by secreting metabolites having an anticancer effect while being established in the gut. In addition, when used in combination with an anticancer chemotherapeutic agent or an anticancer immunotherapeutic agent, the Lactococcus lactis GEN3033 strain of the present invention exhibits a better anticancer effect. ma: Porphyromonadacea b: Prevotellaceae mc: Rikenellaceae Md: Enterococcaceae Me Lactbacillaceae Mf: Leuconostocaceae m :Streptococcaceae mh: unclassified SMi: Lactobacillales mj: Bacilli mk: Clostridiaceae -I: Lachnospiraceae i mRuminococcaceae M n: unclassified Smo Clostridiales - o pClostridia - Mq: Erysipelotrichaceac M r: Erysipelotrichales M s: Erysipelotrichi Mt Comnanonadaceae mu: Burkholderiales M v: Betaproteobacteria \, Mw: Enterobacteriaceae M x: Enterobacteriales my: Gammaproteobacteria M z: Verrucomicrobiaceae Ma: Verrucomicrobiales Mal: Verrucomicrobiae Faecalbacterium_prausnitzu Prevotellacopr Coprococcus unclassified Blautia unclassified Bacteroidesplebeius SMB53_unclassified Lachrnospiraceae_unclassified Megamonasunclassified Bifidobacteriumunclassified Lactobacillales_unclassified Bacteroides_caccae Lactobacillus unclassified Bacteroides uniformis Oscillospiraunclassified Bacteroidesovatus Lactobacillus salivarius Weissellaunclassified Parabacteroidesunclassified Escherichia_coli Bacteroidesfragilis Streptococcus_unclassified Klebsiella_unclassified Akkermansia: muciniphila Clostridiales-unclassified Enterococcus unclassified -4 -2 0 2 4 LDA SCORE (log 10) Lung cancer patients - Normal controls